NASDAQ:MNKD - Get Free Report ) posted its earnings results on Wednesday. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.02, Briefing.com reports. The company had revenue of $66.26 million for the quarter, compared to analyst estimates of $60.55 million. The business's quarterly revenue was up 63.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.04) EPS.
Get MannKind alerts:
Sign Up
MannKind Price Performance MannKind stock traded down $0.07 during midday trading on Wednesday, hitting $4.40. The company's stock had a trading volume of 1,967,717 shares, compared to its average volume of 2,856,611. MannKind has a 1-year low of $3.17 and a 1-year high of $5.75. The company has a 50-day moving average price of $4.46 and a two-hundred day moving average price of $3.93. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -88.00 and a beta of 1.34.
Analyst Upgrades and Downgrades Several research analysts have weighed in on MNKD shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $6.50 price target on shares of MannKind in a report on Friday, March 15th. Wedbush reiterated an "outperform" rating and set a $10.00 target price on shares of MannKind in a research note on Wednesday, February 28th.
Check Out Our Latest Stock Analysis on MannKind
About MannKind (
Get Free Report )
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
See Also
Before you consider MannKind, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.
While MannKind currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
